Clinical Implications of the New Criteria for a Positive Bronchodilator Response in Children With Asthma

IF 2.1 4区 医学 Q1 PEDIATRICS Acta Paediatrica Pub Date : 2025-03-24 DOI:10.1111/apa.70064
Caroline Stridsman, Helena Backman, Lowie E. G. W. Vanfleteren, Anna Asarnoj, Henrik Ljungberg, Anne Lindberg, Apostolos Bossios, Jon R. Konradsen
{"title":"Clinical Implications of the New Criteria for a Positive Bronchodilator Response in Children With Asthma","authors":"Caroline Stridsman,&nbsp;Helena Backman,&nbsp;Lowie E. G. W. Vanfleteren,&nbsp;Anna Asarnoj,&nbsp;Henrik Ljungberg,&nbsp;Anne Lindberg,&nbsp;Apostolos Bossios,&nbsp;Jon R. Konradsen","doi":"10.1111/apa.70064","DOIUrl":null,"url":null,"abstract":"<p>Spirometry aids in diagnosing and monitoring asthma by assessing airflow limitations and bronchodilator (BD) responses [<span>1</span>]. The American Thoracic Society and European Respiratory Society recently updated BD response criteria, now defining a positive response as a &gt; 10% increase in FEV<sub>1</sub> (post-BD) relative to the predicted value. Previously, it required a &gt; 12% and ≥ 200 mL increase from pre-BD values [<span>1</span>]. This change aims to reduce biases related to age, sex, and height, but is based on adult data and unvalidated in children. Paediatric studies have indicated that the new BD response could lead to overdiagnosing asthma [<span>2</span>]. One study reported that children who tested positive, based on the new criteria, had a higher baseline FEV<sub>1</sub>, forced vital capacity (FVC), and FEV<sub>1</sub>/FVC [<span>3</span>].</p><p>We used data from a real-world paediatric, specialist care asthma cohort to explore the concordance between the old and new BD response criteria and the clinical characteristics of the children identified by them. The study complied with the Declaration of Helsinki and was approved by the Swedish Ethical Review Authority (2019-04915). Informed consent was waived.</p><p>Data on asthma diagnoses were extracted from the Swedish National Airway Register [<span>4</span>]. Spirometry data were assessed using pre- and post-bronchodilator FEV<sub>1</sub> and FEV<sub>1</sub>/FVC and are presented as percentages below the lower limit of normal (<i>z</i>-score &lt; −1.645) using references from the Global Lung Initiative [<span>5</span>]. Old BD responses were calculated using the previous definition [<span>1</span>]: ((post-bronchodilator<sub>FEV1</sub> (L) − pre-bronchodilator<sub>FEV1</sub> (L))/pre-bronchodilator<sub>FEV1</sub> (L)) × 100. A change of &gt; 12% and ≥ 200 mL was considered positive. New BD responses were calculated using the updated defintition [<span>1</span>]: ((post-bronchodilator<sub>FEV1</sub> (L) − pre-bronchodilator<sub>FEV1</sub> (L))/predicted value (L)) × 100. A change of &gt; 10% was considered positive. Age was categorised as 5–11 and 12–17 years. The body mass index, calculated as weight (kilograms)/height<sup>2</sup> (meters), was categorised as normal weight or overweight/obesity using age-dependent cut-offs. An asthma control test score of ≤ 19 denoted uncontrolled asthma. Treatment for asthma included bronchodilators, inhaled corticosteroids, leukotriene receptor antagonists, and biological treatments. Treatment was categorised as step 1–2 or step 3–5, as defined by the Global Initiative for Asthma. Statistical analyses were conducted using SPSS Statistics version 29 (IBM Corp, New York, USA). Chi-square tests were used for between-group comparisons, and statistical significance was <i>p</i> &lt; 0.05. Cohen's kappa estimated the agreement between old and new BD responses.</p><p>The study comprised 3301 children aged 5–17 years with complete pre- and post-bronchodilator spirometry data. Both old and new BD responses were negative in 2770 cases (84%) whereas the other 531 (16%) had a positive test result (Table 1). Using the new BD responses yielded more positive results than old BD responses. Almost a third of the children who were positive in one or both tests had discordant results. The kappa value for agreement between the old and new BD responses was 0.79. Positive old BD responses, but negative new BD responses, were found in 30 children (0.9%). These children were older and more likely to have had FEV<sub>1</sub> &lt; LLN and airway obstruction both pre- and post-bronchodilators, compared with the 137 children with negative old BD responses and positive new BD responses (Table 1). Old BD responses were positive in 8.5% with pre-bronchodilator FEV<sub>1</sub> &gt; LLN and new BD responses in 13.1% of that group.</p><p>Two studies have evaluated the impact of the new BD responses on children. A population-based study [<span>2</span>] assessed the spirometry results of 2293 children, including 14.4% with current asthma. New BD responses were positive in 36% with asthma and 25% without, compared to 17% and 10% for the old BD responses. The effects of changing the BD responses were also evaluated using data from a pulmonary function laboratory on 1224 children referred for cough or asthma [<span>3</span>]. The new BD response was positive in 18% and the old BD response in 15%. Children with a positive new BD response had higher baseline FEV<sub>1</sub>, forced vital capacity (FVC) and FEV<sub>1</sub>/FVC than those with a positive old response.</p><p>Our results extend previous findings. They show that children with positive old, but negative new, BD responses differed from children with negative old, but positive new, BD responses. They were older, prescribed more treatment, and had more impaired lung function. When the new BD response was used, children with less asthma morbidity were classified as having a positive bronchodilator response, and a few children with more morbidity were classified as having no bronchodilator response. However, the bronchodilator response is not the only factor used to evaluate troublesome asthma in clinical settings, and current treatment also impacts bronchodilator responses. Nevertheless, the findings underline that bronchodilator responses from adults cannot be extrapolated to children.</p><p>Interestingly, both the old and new BD responses were positive in a significant proportion of children with pre-bronchodilator FEV<sub>1</sub> above the lower limit of normal. This challenges clinical guidelines that only recommend bronchodilator responses in children with pre-bronchodilator airway obstruction.</p><p>The study's strengths included the large cohort and before and after bronchodilator lung function measurements. All the children were diagnosed with asthma and the results are not necessarily generalisable to healthy children or those with suspected asthma. The limitations included no knowledge of adherence to prescribed medications or whether the data originated from new referrals or follow-up visits. Some data on body mass index, asthma control tests, and asthma treatment were also missing. In Sweden, spirometry is generally performed by specialised paediatric nurses and many have national licences to perform this. We can consider that the quality of spirometry was good, even though we did not have access to the original data.</p><p>In conclusion, switching from the old to new BD responses meant that children with less asthma morbidity were classified as having a positive bronchodilator response. A few children with more morbidity were classified as having no bronchodilator response. This underlines that bronchodilator response results from adults cannot be extrapolated to children. Cut-off values balance sensitivity and specificity, and BD responses should be interpreted with other markers and clinical judgement.</p><p><b>Caroline Stridsman:</b> conceptualization, methodology, project administration, resources, writing – review and editing, funding acquisition. <b>Helena Backman:</b> conceptualization, methodology, writing – review and editing. <b>Lowie E. G. W. Vanfleteren:</b> conceptualization, methodology, writing – review and editing. <b>Anna Asarnoj:</b> writing – review and editing, methodology, conceptualization. <b>Henrik Ljungberg:</b> conceptualization, methodology, writing – review and editing. <b>Anne Lindberg:</b> conceptualization, methodology, writing – review and editing. <b>Apostolos Bossios:</b> conceptualization, methodology, writing – review and editing. <b>Jon R. Konradsen:</b> conceptualization, methodology, formal analysis, project administration, writing – original draft, funding acquisition, resources.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":55562,"journal":{"name":"Acta Paediatrica","volume":"114 7","pages":"1731-1733"},"PeriodicalIF":2.1000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apa.70064","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Paediatrica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apa.70064","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Spirometry aids in diagnosing and monitoring asthma by assessing airflow limitations and bronchodilator (BD) responses [1]. The American Thoracic Society and European Respiratory Society recently updated BD response criteria, now defining a positive response as a > 10% increase in FEV1 (post-BD) relative to the predicted value. Previously, it required a > 12% and ≥ 200 mL increase from pre-BD values [1]. This change aims to reduce biases related to age, sex, and height, but is based on adult data and unvalidated in children. Paediatric studies have indicated that the new BD response could lead to overdiagnosing asthma [2]. One study reported that children who tested positive, based on the new criteria, had a higher baseline FEV1, forced vital capacity (FVC), and FEV1/FVC [3].

We used data from a real-world paediatric, specialist care asthma cohort to explore the concordance between the old and new BD response criteria and the clinical characteristics of the children identified by them. The study complied with the Declaration of Helsinki and was approved by the Swedish Ethical Review Authority (2019-04915). Informed consent was waived.

Data on asthma diagnoses were extracted from the Swedish National Airway Register [4]. Spirometry data were assessed using pre- and post-bronchodilator FEV1 and FEV1/FVC and are presented as percentages below the lower limit of normal (z-score < −1.645) using references from the Global Lung Initiative [5]. Old BD responses were calculated using the previous definition [1]: ((post-bronchodilatorFEV1 (L) − pre-bronchodilatorFEV1 (L))/pre-bronchodilatorFEV1 (L)) × 100. A change of > 12% and ≥ 200 mL was considered positive. New BD responses were calculated using the updated defintition [1]: ((post-bronchodilatorFEV1 (L) − pre-bronchodilatorFEV1 (L))/predicted value (L)) × 100. A change of > 10% was considered positive. Age was categorised as 5–11 and 12–17 years. The body mass index, calculated as weight (kilograms)/height2 (meters), was categorised as normal weight or overweight/obesity using age-dependent cut-offs. An asthma control test score of ≤ 19 denoted uncontrolled asthma. Treatment for asthma included bronchodilators, inhaled corticosteroids, leukotriene receptor antagonists, and biological treatments. Treatment was categorised as step 1–2 or step 3–5, as defined by the Global Initiative for Asthma. Statistical analyses were conducted using SPSS Statistics version 29 (IBM Corp, New York, USA). Chi-square tests were used for between-group comparisons, and statistical significance was p < 0.05. Cohen's kappa estimated the agreement between old and new BD responses.

The study comprised 3301 children aged 5–17 years with complete pre- and post-bronchodilator spirometry data. Both old and new BD responses were negative in 2770 cases (84%) whereas the other 531 (16%) had a positive test result (Table 1). Using the new BD responses yielded more positive results than old BD responses. Almost a third of the children who were positive in one or both tests had discordant results. The kappa value for agreement between the old and new BD responses was 0.79. Positive old BD responses, but negative new BD responses, were found in 30 children (0.9%). These children were older and more likely to have had FEV1 < LLN and airway obstruction both pre- and post-bronchodilators, compared with the 137 children with negative old BD responses and positive new BD responses (Table 1). Old BD responses were positive in 8.5% with pre-bronchodilator FEV1 > LLN and new BD responses in 13.1% of that group.

Two studies have evaluated the impact of the new BD responses on children. A population-based study [2] assessed the spirometry results of 2293 children, including 14.4% with current asthma. New BD responses were positive in 36% with asthma and 25% without, compared to 17% and 10% for the old BD responses. The effects of changing the BD responses were also evaluated using data from a pulmonary function laboratory on 1224 children referred for cough or asthma [3]. The new BD response was positive in 18% and the old BD response in 15%. Children with a positive new BD response had higher baseline FEV1, forced vital capacity (FVC) and FEV1/FVC than those with a positive old response.

Our results extend previous findings. They show that children with positive old, but negative new, BD responses differed from children with negative old, but positive new, BD responses. They were older, prescribed more treatment, and had more impaired lung function. When the new BD response was used, children with less asthma morbidity were classified as having a positive bronchodilator response, and a few children with more morbidity were classified as having no bronchodilator response. However, the bronchodilator response is not the only factor used to evaluate troublesome asthma in clinical settings, and current treatment also impacts bronchodilator responses. Nevertheless, the findings underline that bronchodilator responses from adults cannot be extrapolated to children.

Interestingly, both the old and new BD responses were positive in a significant proportion of children with pre-bronchodilator FEV1 above the lower limit of normal. This challenges clinical guidelines that only recommend bronchodilator responses in children with pre-bronchodilator airway obstruction.

The study's strengths included the large cohort and before and after bronchodilator lung function measurements. All the children were diagnosed with asthma and the results are not necessarily generalisable to healthy children or those with suspected asthma. The limitations included no knowledge of adherence to prescribed medications or whether the data originated from new referrals or follow-up visits. Some data on body mass index, asthma control tests, and asthma treatment were also missing. In Sweden, spirometry is generally performed by specialised paediatric nurses and many have national licences to perform this. We can consider that the quality of spirometry was good, even though we did not have access to the original data.

In conclusion, switching from the old to new BD responses meant that children with less asthma morbidity were classified as having a positive bronchodilator response. A few children with more morbidity were classified as having no bronchodilator response. This underlines that bronchodilator response results from adults cannot be extrapolated to children. Cut-off values balance sensitivity and specificity, and BD responses should be interpreted with other markers and clinical judgement.

Caroline Stridsman: conceptualization, methodology, project administration, resources, writing – review and editing, funding acquisition. Helena Backman: conceptualization, methodology, writing – review and editing. Lowie E. G. W. Vanfleteren: conceptualization, methodology, writing – review and editing. Anna Asarnoj: writing – review and editing, methodology, conceptualization. Henrik Ljungberg: conceptualization, methodology, writing – review and editing. Anne Lindberg: conceptualization, methodology, writing – review and editing. Apostolos Bossios: conceptualization, methodology, writing – review and editing. Jon R. Konradsen: conceptualization, methodology, formal analysis, project administration, writing – original draft, funding acquisition, resources.

The authors declare no conflicts of interest.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
哮喘儿童支气管扩张剂阳性反应新标准的临床意义。
肺活量测定法通过评估气流限制和支气管扩张剂(BD)反应[1],有助于诊断和监测哮喘。美国胸科学会和欧洲呼吸学会最近更新了BD反应标准,现在将FEV1 (BD后)相对于预测值增加10%定义为阳性反应。以前,它需要比bd前的值增加12%和≥200ml。这一改变旨在减少与年龄、性别和身高有关的偏见,但这是基于成人数据,在儿童中未经验证。儿科研究表明,新的双相障碍反应可能导致过度诊断哮喘。一项研究报告,根据新标准,检测呈阳性的儿童有更高的基线FEV1、强迫肺活量(FVC)和FEV1/FVC[3]。我们使用来自真实世界的儿科,专科护理哮喘队列的数据来探索新旧双相障碍反应标准与他们确定的儿童临床特征之间的一致性。该研究符合赫尔辛基宣言,并得到了瑞典伦理审查局(2019-04915)的批准。知情同意被放弃。哮喘诊断数据来自瑞典国家气道登记([4])。肺活量测定数据采用支气管扩张剂使用前和使用后的FEV1和FEV1/FVC进行评估,并以低于正常下限的百分比表示(z-score &lt; - 1.645),参考文献来自Global Lung Initiative[5]。使用先前的定义[1]计算老年BD反应:((支气管扩张剂后fev1 (L)−支气管扩张剂前fev1 (L))/支气管扩张剂前fev1 (L)) × 100。变化&gt; 12%且≥200 mL为阳性。使用更新后的定义[1]计算新的BD反应:((支气管舒张后fev1 (L)−支气管舒张前fev1 (L))/预测值(L)) × 100。10%的变化被认为是积极的。年龄分为5-11岁和12-17岁。体重指数以体重(公斤)/身高(米)计算,并根据年龄划分为正常体重或超重/肥胖。哮喘控制测试得分≤19分为哮喘未控制。哮喘的治疗包括支气管扩张剂、吸入皮质类固醇、白三烯受体拮抗剂和生物治疗。根据全球哮喘倡议的定义,治疗分为步骤1-2或步骤3-5。使用SPSS Statistics version 29 (IBM Corp, New York, USA)进行统计分析。组间比较采用卡方检验,p &lt; 0.05为统计学意义。Cohen的kappa估计了新旧BD反应之间的一致性。该研究包括3301名5-17岁的儿童,他们在使用支气管扩张剂前和后都有完整的肺活量测定数据。2770例(84%)患者新旧BD反应均为阴性,而另外531例(16%)患者检测结果为阳性(表1)。使用新的双相反应比使用旧的双相反应产生更积极的结果。在一项或两项测试中呈阳性的儿童中,几乎有三分之一的结果不一致。新旧BD反应一致性kappa值为0.79。30例患儿(0.9%)出现旧性双相障碍反应阳性,新性双相障碍反应阴性。与137例既往BD反应阴性和新BD反应阳性的儿童相比,这些儿童年龄较大,在使用支气管扩张剂前和使用支气管扩张剂后更容易发生FEV1 &lt; LLN和气道阻塞(表1)。在使用支气管扩张剂前FEV1 &gt; LLN的患者中,旧BD反应为8.5%,新BD反应为13.1%。两项研究评估了新的双相障碍对儿童的影响。一项基于人群的研究[2]评估了2293名儿童的肺活量测定结果,其中14.4%患有哮喘。36%的哮喘患者和25%的无哮喘患者出现新的双相障碍反应,相比之下,旧双相障碍反应的患者分别为17%和10%。利用肺功能实验室对1224名咳嗽或哮喘患儿的数据,还对改变BD反应的影响进行了评估。新BD患者的阳性反应率为18%,旧BD患者的阳性反应率为15%。新发病BD反应阳性的患儿FEV1、用力肺活量(FVC)和FEV1/FVC基线值高于旧发病反应阳性的患儿。我们的结果扩展了以前的发现。结果表明,旧双相障碍反应呈阳性但新双相障碍反应呈阴性的儿童与旧双相障碍反应呈阴性但新双相障碍反应呈阳性的儿童不同。他们年龄更大,接受的治疗更多,肺功能受损更严重。当使用新的BD反应时,哮喘发病率较低的儿童被归类为支气管扩张剂阳性反应,而少数发病率较高的儿童被归类为无支气管扩张剂反应。然而,支气管扩张剂的反应并不是临床评估哮喘的唯一因素,目前的治疗也会影响支气管扩张剂的反应。 然而,研究结果强调成人的支气管扩张剂反应不能外推到儿童身上。有趣的是,在支气管扩张剂前FEV1高于正常下限的儿童中,新旧BD反应均为阳性。这挑战了临床指南,即只推荐支气管扩张剂前气道阻塞的儿童使用支气管扩张剂。该研究的优势包括大队列和支气管扩张剂前后的肺功能测量。所有儿童都被诊断患有哮喘,结果不一定适用于健康儿童或疑似哮喘儿童。限制包括不知道是否遵守处方药,或者数据是否来自新转诊或随访。一些关于体重指数、哮喘控制测试和哮喘治疗的数据也缺失。在瑞典,肺活量测定通常由专门的儿科护士进行,许多人都有执行这项工作的国家许可证。我们可以认为肺活量计的质量是好的,即使我们没有获得原始数据。总之,从旧的BD反应转变为新的BD反应意味着哮喘发病率较低的儿童被归类为支气管扩张剂阳性反应。少数发病率较高的儿童被归类为无支气管扩张剂反应。这强调成人的支气管扩张剂反应结果不能外推到儿童。临界值平衡敏感性和特异性,BD反应应与其他标志物和临床判断一起解释。卡洛琳·斯特里兹曼:概念化,方法论,项目管理,资源,写作-审查和编辑,资金获取。海伦娜·贝克曼:概念,方法,写作-审查和编辑。范夫特伦:概念、方法、写作、评论与编辑。Anna Asarnoj:写作——评论和编辑,方法论,概念化。Henrik Ljungberg:概念化,方法论,写作-评论和编辑。安妮·林德伯格:概念化,方法论,写作-评论和编辑。使徒波西奥斯:概念、方法论、写作——审查和编辑。Jon R. Konradsen:概念化,方法论,形式分析,项目管理,撰写原稿,资金获取,资源。作者声明无利益冲突。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Paediatrica
Acta Paediatrica 医学-小儿科
CiteScore
6.50
自引率
5.30%
发文量
384
审稿时长
2-4 weeks
期刊介绍: Acta Paediatrica is a peer-reviewed monthly journal at the forefront of international pediatric research. It covers both clinical and experimental research in all areas of pediatrics including: neonatal medicine developmental medicine adolescent medicine child health and environment psychosomatic pediatrics child health in developing countries
期刊最新文献
Paediatric Primary Care Across Europe: A Survey of 42 Countries. The Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity. Regulatory Problems in Infancy: Prevalence and Association With Early Neurodevelopmental and Medical Conditions in Toddlers. Sociodemographic Factors Associated With Psychological Aggression Toward Children in Bangladesh Based on Nationally Representative Data. Behavioural and Emotional Symptoms Did not Increase During the COVID-19 Pandemic in Swedish Preschool Children.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1